Meta-analysis · people
Semaglutide: 11.85% more weight loss than placebo without diabetes
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
Pooled trial data in people without diabetes show clear extra weight loss over placebo, along with a higher risk of gut side effects, stopping treatment and serious events such as pancreatitis and gallstones.
- Kind
- Meta-analysis
- Studied in
- People
- Number studied
- 3613
- Published
- 2022
- Journal
- J ASEAN Fed Endocr Soc
What they tested
The team wanted to know how well semaglutide shots work for weight loss in people with obesity who don't have diabetes, and how safe they are.
How the study was done
A systematic review and meta-analysis, which pools the results of several studies, of 4 randomized controlled trials with 3,613 people with obesity and no diabetes. It compared semaglutide given as an injection under the skin with placebo, a dummy shot.

Model. Individual results vary.
What they found
Across the pooled trials, people on semaglutide lost 11.85% more of their starting weight than those on placebo (95% CI -12.81 to -10.90). Stomach and gut side effects were more common with semaglutide, with a risk ratio, the risk compared with placebo, of 1.59. Stopping treatment because of side effects had a risk ratio of 2.19, and serious side effects had a risk ratio of 1.60. Most serious events involved the gut, liver or gallbladder, such as acute pancreatitis, an inflamed pancreas, and gallstones.
What it doesn’t show
The analysis rests on only 4 trials and covers only semaglutide given as a shot under the skin. It doesn't apply to people with type 2 diabetes, who were not included.
The paper
Tan et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1Randomized trial · people · 2025
- CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2Randomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.